<DOC>
	<DOCNO>NCT01207128</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic effectiveness combination antifungal therapy ( CAT ) voriconazole plus micafungin versus voriconazole plus placebo equivalent primary therapy invasive aspergillosis ( IA ) patient hematological cancer .</brief_summary>
	<brief_title>Trial Combination Antifungal Therapy ( Vori+Mica vs. Vori+Placebo ) Invasive Aspergillosis</brief_title>
	<detailed_description>Patients receive either IV micafungin 100 mg placebo equivalent daily . Intravenous ( IV ) Voriconazole administer load dose 6 mg/kg every 12 hour first 24 hour follow maintenance dose 4 mg/kg every 12 hour . Patients may switch oral voriconazole 200 mg BID provide aspergillosis response achieve gastrointestinal function intact .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>1 . The patient legally authorize representative sign informed consent/assent . Assent obtain require UAMS IRB . 2 . The patient diagnosis proven probable invasive aspergillosis positive Aspergillus GM index ( â‰¥0.5 ng/ml ) provide patient receiving antibiotic , piperacillintazobactam , know cause false positive GMI 3 . The patient 18 year age old . 1 . The patient treat unlicensed investigational drug aspergillosis . 2 . The patient administer antifungal agent ( voriconazole , itraconazole , posaconazole , caspofungin , micafungin , anidulafungin , amphotericin B , lipid formulation amphotericin B ) &gt; 7 day immediately prior randomization treatment Probable , Proven invasive aspergillosis patient enrol . 3 . Patient invasive aspergillosis negative Aspergillus GM index . 4 . The patient pregnant lactating . If patient female childbearing potential , patient must negative pregnancy test avoid become pregnant receiving study drug . A pregnancy test perform within 14 day prior first dose study drug . 5 . The patient alkaline phosphatase , ALT , AST total bilirubin great five time upper limit normal . 6 . The patient hepatic cirrhosis . 7 . Patients creatinine &gt; 3 enrol able receive oral voriconazole ( specify oral loading dose 6 mg/kg PO Q 12 hour 24 hour ) oral maintenance 200 mg PO q 12 hour ) . 8 . The patient artificial ventilation , unlikely extubated within 24 hour study entry . 9 . The patient history allergy , hypersensitivity , serious reaction azole echinocandin class antifungal agent . 10 . The patient previously enrol study . 11 . The patient concomitant medical condition , opinion Investigator may create unacceptable additional risk . 12 . The patient active microbiologicallydocumented deep infection due nonAspergillus mold . 13 . The patient life expectancy less seven day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>